

<!-- page 1 -->

I fldgi ( ^ I& fPoh - YS% ,xld m%cd;dka;s%l iudcjd§ ckrcfha w;s úfYI .eiÜ m;%h - 2020'01'24
PART I : SEC. (I) - GAZETTE EXTRAORDINARY OF THE  DEMOCRATIC SOCIALIST REPUBLIC OF SRI LANKA - 24.01.2020
1A
w;s úfYI
wxl 2159$49 - 2020 ckjdß ui 24 jeks isl=rdod - 2020'01'24
No. 2159/49  -  FRIDAY,  JANUARY  24,  2020
EXTRAORDINARY
Y%S ,xld m%cd;dka;%sl iudcjd§ ckrcfha .eiÜ m;%h
The Gazette of the Democratic Socialist Republic of Sri Lanka
(Published by Authority)
PART I : SECTION (I) — GENERAL
Government  Notifications
                  
       
              
               
            
        
                  
     
         
             
         
               
            
               
               
            
               
        
                 
        
              
               
            
         
                  
CONVENTION   AGAINST  DOPING  IN   SPORTS  ACT,   No.  33   OF  2013
REGULATIONS made by the Minister of  Sports under Section 34 read with Section 3 of the Convention against Doping
in Sport  Act, No. 33 of 2013.
DALLAS ALAHAPPERUMA (M. P.),
Minister of Education, Sports
and Youth Affairs.
Colombo,
23rd December, 2019.
Regulations
1. These regulations may be cited as the Anti-Doping (Prohibited List) Regulations  No. 05 of 2019.
2. These regulations shall be deemed to have come into  operation on  1
st, January 2019.
The 2020 prohibited List
2019 October.
This Gazette Extraordinary can be downloaded from www.documents.gov.lk
1A - PG   4833 — 517 (12/2019)


<!-- page 2 -->

I fldgi ( ^ I& fPoh - YS% ,xld m%cd;dka;s%l iudcjd§ ckrcfha w;s úfYI .eiÜ m;%h - 2020'01'24
PART I : SEC. (I) - GAZETTE EXTRAORDINARY OF THE  DEMOCRATIC SOCIALIST REPUBLIC OF SRI LANKA - 24.01.2020
2A
THE   WORLD   ANTI-DOPING   CODE
THE   2019 P ROHIBITED LIST
INTERNATIONAL  STANDARD
The Official text of the Prohibited List  shall be maintained by WADA and shall be published in English and
French. In the event of any conflict between the English and French versions,  the English  version shall prevail.
This List shall come into effect on 01 st  January, 2019.
THE  WORLD    ANTI-DOPING    CODE
INTERNATIONAL   STANDARD
PROHIBITED    LIST
JANUARY 2020
This List shall come into effect on 01 st January 2020
IN ACCORDANCE WITH ARTICLE  4.2.2 OF THE WORLD ANTI-DOPING CODE, ALL PROHIBITED SUBSTANCES
SHALL  BE CONSIDERED  AS “SPECIFIED SUBSTANCES” EXCEPT SUBSTANCES IN CLASSES S1, S2, S4.4,  S4.5,
S6.A, AND PROHIBITED METHODS  M1, M2 AND M3
SUBSTANCES    AND    METHODS    PROHIBITED    AT    ALL   TIMES
(IN-AND  OUT-OF-COMPETITION)
PROHIBITED    SUBSTANCES
S0-NON-APPROVED   SUBSTANCES
Any pharmacological substance which is not addressed  by any of the subsequent sections of the List and with no current
approval by any governmental  regulatory health authority for human therapeutic use ( e.g. drugs under pre-clinical or
clinical development or discontinued, designer drugs, substances approved only for veterinary use) is prohibited at all
times.
S1.   ANABOLIC   AGENTS
Anabolic agents are prohibited.
1. ANABOLIC  ANDROGENIC  STEROIDS (AAS)
When administered exogenously, including but not limited to :
1- Androstenediol 
(5-androst-1-ene-317-diol); 1-Androstenedione (5-androst-1-ene-3,17-dione); 1-Androsterone (3--hydroxy-
5-androst-1-ene-17-one); 1-Epiandrosterone (-hydroxy-5-androst-1-ene-17-one) ;1-Testosterone [-hydroxy-5-androst-1-en-3-
one]; 4-Androstenediol  (androst-4-ene-3 ,17-diol); 4-Hydroxtestosterone (4,  dihydroxyandrost -4-en-3-one); 5-
Androstenedione (androst-5-ene-3,17-dione); 7-Hydroxy-DHEA ; 7-Hydroxy-DHEA ; 7-Keto-DHEA ; 19-Norandrostenediol
(estr-4-ene-3,17-diol); 19-Norandrostenedione (estr-4-ene-3,17-dione); Androstanolone [5-dihydrotestosterone, 17-hydroxy-5
androstan-3 - one]; Androstenediol (androst-5-ene-317-diol) ; Androstenedione (androst-4-ene-3,17-dione) ; Bolasterone; Boldenone;
Boldione (androsta-1, 4-diene-3 17-Dione) ; Calusterone; Clostebol; Danazol ([1,2]oxazolo[4',5':2,3]pregna-4-en-20-yn-17-ol);
Dehydrochlormethyltestosterone (4-chloro--hydroxy--methylandrosta-1,4-dien-3-one); Desoxymethyltestosterone (-methyl-
5-androst-2-en--ol and -methyl-5-androst-3-en--ol ; Drostanolone ; Epiandrosterone (3-hydroxy-5-androstan-17-one)
; Epi-dihydrotestosterone  (17 -hydroxy-5 -androstan-3-one) ; Epiandrosterone  ;  Ethylestrenol  (19-norpregna-4-en-17 -
ol);Fluoxymesterone;  Formebolone; Furazabol (-methyl[1,2,5]oxadiazolo[3',4':2,3]-5-androstan--ol);Gestrinone; Mestanolone,
Mesterolone, Metandienone (-hydroxy-17-methylandrosta-1,4-dien-3-one);Metenolone; Methandriol; Methasterone (-hydroxy-
2,17-dimethyl-5-androstan-3-one);  Methyl-1-testosterone ( -hydroxy-17-methyl-5-androst-1-en-3-one); Methylclostebol ;
Methyldienolone (-hydroxy-17-methylestr-4, 9-dien-3 one) ;  Methylnortestosterone (-hydroxy-17-methylestr-4-en-3 one)
;Methyltestosterone; Metribolone (methyltrienolone,-hydroxy-17-methylestra-4,9,11-trien-3-one);Mibolerone;  Nandrolone (19 -
nortestosterone) ; Norboletone  ; Norclostebol (-chloro-17 -ol-estr-4-en-3-one) ; Norethandrolone; Oxabolone; Oxandrolone ;

<!-- page 3 -->

I fldgi ( ^ I& fPoh - YS% ,xld m%cd;dka;s%l iudcjd§ ckrcfha w;s úfYI .eiÜ m;%h - 2020'01'24
PART I : SEC. (I) - GAZETTE EXTRAORDINARY OF THE  DEMOCRATIC SOCIALIST REPUBLIC OF SRI LANKA - 24.01.2020
3A
Oxymesterone; Oxymetholone; Prasterone  (dehydroepiandrosterone, DHEA, 3- hydroxyandrost-5-en-17-one) ; Prostanozol (-
[(tetrahydropyran-2-yl)oxy]-1'H-pyrazolo[3,4:2,3]-5-androstane); Quinbolone ; Stanozolol ; Stenbolone;Testosterone; Tetrahydrogestrinone
(-hydroxy-18a-homo-19-nor-17-pregna-4,9,11-trien-3-one); Trenbolone  (-hydroxyestr-4,9,11-trien-3-one); and  other substances
with a similar chemical structure or similar biological effect (s).
  2. OTHER   ANABOLIC   AGENTS
Including, but not limited to:
Clenbuterol, selective androgen receptor modulators  (SARMs; e.g. andarine LGD-4033, enobosarm (ostarine) and
RAD 140), Tibolone, Zeranol and Zilpaterol.
S2. PEPTIDE  HORMONES,   GROWTH     FACTORS,   RELATED    SUBSTANCES   AND   MIMETICS
The following substances, and other substances with similar chemical structure or similar  biological effect(s), are
prohibited:
1. Erythropoietin [EPO] - and agents affecting erythropoiesis, including but not limited to :
1.1. Er ythropoietin - Receptor Agonists , e. g.
Darbepoietins (dEPO); Erythropoietins (EPO) ; EPO based constructs [e. g. EPO-Fc, methoxy polyethylene
glycol -epoetin beta [CERA]] ;EPO-mimetic agents and their constructs, [e.g. CNTO 530 and peginesatide] ;
1.2 Hypoxia - inducible factor (HIF) activating agents e.g. Argon ; Cobalt ; Daprodustat (GSK 1278863)
Molidustat (BAY 85-3934) ; Roxadustat  [FG-4592]; Vadadustat (AKB-6548) ; Xenon
1.3 GATA inhibitors, e. g. K-11706
1.4 TGF - beta [TGF -] signalling inhibitors, e.g. ; Luspatercept ; Sotatercept
1.5 Innate repair receptor agonists, e. g.
Asialo EPO ;
Carbamylated EPO [CEPO].
2. Peptide Hormones and their releasing factors.
2.1 Chorionic Gonadotrophin [CG[ and Luteinizing  Hormone (LH) and their releasing factors in males, e.g.
Buserelin,  deslorelin, gonadorelin, goserelin, leuprorelin, nafarelin and triptorelin ;
2.2 Corticotrophins and their releasing factors, e. g. Corticorelin ;
2.3 Growth Hormone  [GH[ its fragments and releasing factors, including but not limited to :
Growth Hormone fragments, e. g. AOD - 9604 and hGH 176-191 ;
Growth Hormone Releasing Hormone [GHRH] and its analogues, e. g. CJC - 1293, CJC - 1295,
sermorelin and tesamorelin ;
Growth Hormone Secretagogues  [GHS[, e. g. Lenomorelin (ghrelin) and its mimetics, e. g. Anamorelin,
ipamorelin, macimorelin and tabimorelin ;
GH - Releasing Peptides  (GHRPs), e.g. Alexamorelin,  GHRP - 1, GHRP - 2 [pralmoralin], GHRP - 3,
GHRP - 4, GHRP - 5, GHRP - 6 and examorelin [hexarelin].
3. Growth Factors and Growth Factor Modulators, including but not limited to ;
Fibroblast Growth Factors  (FGFs); Hepatocyte Growth Factor  (HGF); Insulin-like Growth Factor - 1
(IGF-1)  and its analogues; Mechano Growth Factors  (MGFs); Platelet-Derived Growth Factor  (PDGF);
Thymosin - 
4 and its derivatives e. g. TB - 500 ; Vascular-Endothelial Growth Factor  (VEGF) and
other growth factors or growth modulators affecting muscle, tendon or ligament protein synthesis/degradation,
vascularisation, energy utilization, regenerative capacity, or fibre type switching.

<!-- page 4 -->

I fldgi ( ^ I& fPoh - YS% ,xld m%cd;dka;s%l iudcjd§ ckrcfha w;s úfYI .eiÜ m;%h - 2020'01'24
PART I : SEC. (I) - GAZETTE EXTRAORDINARY OF THE  DEMOCRATIC SOCIALIST REPUBLIC OF SRI LANKA - 24.01.2020
4A
S3. BETA - 2 AGONISTS
All selective and non-selective beta-2 agonists, including all optical isomers, are prohibited.
Including, but not limited to :
Fenoterol ; Formoterol ; Higenamine ; Indacaterol ; Olodaterol ; Procaterol ; Reproterol ; Salbutamol ; Salmeterol ;
Terbutaline ; Tretoquinol (trimetoquinol) ; Tulobuterol ; Vilanterol ;
Except :
* Inhaled salbutamol : maximum 1600 micrograms over 24 hours in divided doses not to exceed 800 micrograms
over 12 hours starting from any dose ;
* Inhaled formoterol : maximum delivered dose of 54  micrograms over 24 hours ;
* Inhaled salmeterol  : maximum 200 micrograms over 24 hours.
The presence in urine of salbutamol in excess of 1000 ng/mL or formoterol in excess of 40ng/mL is not consistent with
therapeutic use of the substance and will be considered as an Adverse Analytical Finding (AAF) unless the Athlete
proves, through  a controlled pharmacokinetic study, that the abnormal result was the consequence of a therapeutic dose (by
inhalation) up to the maximum indicated above.
S4.   HORMONE   AND   METABOLIC   MODULATORS
The following hormone and metabolic modulators are prohibited:
1. Aromatase inhibitors including, but not limited to: 2-Androstenol (5
-androst-2-en-17-ol) ; 2-Androstenone
(5-androst 2-en-17-one) ; 3-Androstenol (5 -androst-3-en-17-ol) ; 3-Androstenone (5 -androst-3-en-
17-one) ; 4-Androstene-3, 6, 17 trione (6-oxo) ; Aminoglutethimide; Anastrozole; Androsta - 1,4,6,-triene-
3,17-dione  (androstatrienedione);  Androsta-3,5-diene-7, 17-dione  (arimistane); Exemestane; Formestane;
Letrozole;  Testolactone.
2. Selective estrogen receptor modulators (SERMs) including, but not limited to : Bazedoxifene; Ospemifene ; Raloxifene;
Tamoxifen ;  Toremifene.
3. Other anti-estrogenic substances  including, but not limited to: Clomifene; Cyclofenil and Fulvestrant .
4. Agents preventing activin receptor IIB activation including, but not limited, to :
Activin A - neutralizing antibodies ; Activin receptor IIB competitors such as ; Decoy activin receptors (e. g.
ACE - 031) ; Anti-activin receptor IIB antibodies ( e. g. Bimagrumab) ; Myostatin inhibitors such as : Agents
reducing or ablating myostatin expression ; Myostatin - binding proteins ( e. g. follistatin, myostatin propetide) ;
Mayostatin - neutralizing antibodies ( e. g. Domagrozumab, landogrozumab, stamulumab)
5. Metabolic  modulators:
5.1 Activators of the AMP-activated protein kinase (AMPK) e.g. AICAR SR9009 ; and Peroxisome Proliferator
Activated Receptor  (PPAR)  agonists, e.g. 2-[2-methyl-4-[[4-methyl-2-[4-[trifluoromethyl] phenyl] thiazol-5-yl]
methylthio] phenoxyl] acetic acid [GW1516, GW501516] ;
5.2 Insulins and Insulin - Mimetics ;
5.3 Meldonium ;
5.4 Trimetazidine.

<!-- page 5 -->

I fldgi ( ^ I& fPoh - YS% ,xld m%cd;dka;s%l iudcjd§ ckrcfha w;s úfYI .eiÜ m;%h - 2020'01'24
PART I : SEC. (I) - GAZETTE EXTRAORDINARY OF THE  DEMOCRATIC SOCIALIST REPUBLIC OF SRI LANKA - 24.01.2020
5A
S5. DIURETICS    AND   MASKING    AGENTS
The following  diuretics, and masking agents are prohibited, as are other substances with a similar chemical structure or
similar biological effect (s).
Including, but not limited to:
* Desmopressin; probenecid; plasma expanders, e.g. intravenous administration of albumin, dextran,
hydroxyethyl starch and mannitol ;
* Acetazolamide; amiloride;  bumetanide; canrenone; chlortalidone;  etacrynic acid; furosemide; indapamide;
metolazone; spironolactone; thiazides, e.g. Bendroflumethiazide, chlorothiazide and hydrochlorothiazide;
triamterene and vaptans, e.g. tolvaptan.
Except:
Drospirenone; pamabrom; and ophthalmic use of carbonic anhydrase inhibitors (e.g. Dorzolamide,
brinzolamide) ;
Local administration of felypressin in dental anesthesia.
The detection in an Athlete’s Sample at all times or In -Competition, as applicable, of any quantity of the following
substances subject to threshold limits: formoterol, salbutamol, cathine, ephedrine, methylephedrine and pseudoephedrine,
in conjunction with a diuretic or masking agent, will be considered as an Adverse Analytical Finding (AAF) unless the
Athlete has an approved Therapeutic Use Exemption (TUE) for that substance in addition to the one granted for the
diuretic or masking agent.
PROHIBITED   METHODS
M1.  MANIPULATION    OF    BLOOD   AND   BLOOD    COMPONENTS
The following  are prohibited:
1. The Administration or reintroduction of any quantity of autologous, allogenic (homologous) or heterologous
blood, or red blood cell products of any origin into the circulatory system.
2. Artificially enhancing the uptake, transport or delivery of  oxygen.
Including, but not limited to:
Perfluorochemicals; efaproxiral (RSR 13) and modified  haemoglobin products, e.g. Haemoglobin-based blood
substitutes and microencapsulated haemoglobin  products, excluding supplemental oxygen by inhalation.
3. Any form of intravascular manipulation of the blood or blood components by physical or chemical means.
M2.  CHEMICAL    AND   PHYSICAL    MANIPULATION
The following are prohibited:
1. Tampering, or Attempting to Tamper, to alter the integrity and  validity of Samples collected during Doping Control.
Including, but not limited to:
Sample substitution and/or adulteration, e.g. Addition of Proteases to the sample.
2. Intravenous infusions and /or injections of more than a total of 100mL per 12 hour period except for those
legitimately received in the course of hospital treatments, surgical procedures or clinical investigations.

<!-- page 6 -->

I fldgi ( ^ I& fPoh - YS% ,xld m%cd;dka;s%l iudcjd§ ckrcfha w;s úfYI .eiÜ m;%h - 2020'01'24
PART I : SEC. (I) - GAZETTE EXTRAORDINARY OF THE  DEMOCRATIC SOCIALIST REPUBLIC OF SRI LANKA - 24.01.2020
6A
M3.  GENE  DOPING  AND  CELL  DOPING
The following with the potential to enhance sport performance, are prohibited:
1. The use of nucleic acids or nucleic acid analogues that may alter genome sequences and/or alter gene
expression by any mechanism. This includes but is not limited to gene editing, gene silencing and gene transfer
technologies ;
2. The use of normal or genetically modified cells.
SUBSTANCES   AND    METHODS
PROHIBITED IN- COMPETITION
IN ADDITION TO  THE  CLASSES  S0 TO  S5  AND M1  TO  M3  DEFINED  ABOVE,
THE   FOLLOWING  CLASSES  ARE  PROHIBITED  IN - COMPETITION:
PROHIBITED    SUBSTANCES
S6. STIMULANTS
All stimulants, including all optical isomers, e.g. d- and l- where relevant, are prohibited.
Stimulants include:
(a) Non- Specified Stimulants :
Adrafinil; Amfepramone; Amfetamine; Amfetaminil; Amiphenazole; Benfluorex; Benzylpiperazine; Bromantan;
Clobenzorex; Cocaine; Cropropamide; Crotetamide; Fencamine; Fenetylline; Fenfluramine; Fenproporex; Fonturacetam
[4- phenylpiracetam (carphedon)] ; Furfenorex; Lisdexamfetamine; Mefenorex; Mephentermine; Mesocarb; Metamfetamine
( d-) ; p- methylamphetamine; Modafinil; Norfenfluramine; Phendimetrazine; Phentermine; Prenylamine  Prolintane.
A stimulant not expressly  listed in this section is a Specified Substance.
b. Specified Stimulants.
Including, but not limited to:
3-Methylhexan-2-amine (1, 2-dimethylpentylamine); 4-Methylhexan-2-amine (methylhexaneamine); 4-Methylpentan-
2-amine (1, 3-dimethylbutylamine); 5-Methylhexan-2-amine (1,4-dimethylpentylamine) ; Benzfetamine; Cathine**;
Cathinone and its analogues, e.g. mephedrone, methedrone, and   -pyrrolidinovalerophenone; Dimetamfetamine
(dimethylamphetamine); Ephedrine ***; Epinephrine**** (adrenaline); Etamivan; Etilamfetamine;  Etilefrine;
Famprofazone; Fenbutrazate; Fencamfamin; Heptaminol; Hydroxyamfetamine (parahydroxyamphetamine); Isometheptene;
Levmetamfetamine;  Meclofenoxate; Methylenedioxymethamphetamine; Methylephedrine***;  Methylphenidate;
Nikethamide, Norfenefrine; Octodrine (1,5 - dimethylhexylamine) ; Octopamine; Oxilofrine (methylsynephrine) ;
Pemoline; Pentetrazol; Phenethylamine and its derivatives; Phenmetrazine; Phenpromethamine; Propylhexedrine;
Pseudoephedrine*****; Selegiline; Sibutramine; Strychnine; Tenamfetamine (methylenedioxyamphetamine),
Tuaminoheptane;  and other substances with a similar chemical structure or similar biological effect(s).
Except:
* Clonidine
* Imidazole derivatives for dermatological nasal or  ophthalmic use and those stimulants included in the 2020 Monitoring
Program*.
* Bupropion, caffeine, nicotine, phenylephrine, phenylpropanolamine, pipradrol, and synephrine; These substances are
included in the 2020 Monitoring Program, and are not considered Prohibited Substances .

<!-- page 7 -->

I fldgi ( ^ I& fPoh - YS% ,xld m%cd;dka;s%l iudcjd§ ckrcfha w;s úfYI .eiÜ m;%h - 2020'01'24
PART I : SEC. (I) - GAZETTE EXTRAORDINARY OF THE  DEMOCRATIC SOCIALIST REPUBLIC OF SRI LANKA - 24.01.2020
7A
** Cathine: Prohibited when its concentration in urine is greater than 5 micrograms per milliliter.
*** Ephedrine and methylephedrine:  Prohibited when the concentration of either in urine is greater than 10  micrograms
per milliliter.
**** Epinephrine (adrenaline): Not prohibited in local administration, e.g. nasal, ophthalmologic, or co-administration
with local anaesthetic agents.
***** Pseudoephedrine: Prohibited when its concentration in urine is greater than 150 micrograms per milliliter.
S7. NARCOTICS
The following narcotics including all optical isomers, e. g. d-and- 1- where relevant are prohibited:
Buprenorphine; Dextromoramide;  Diamorphine (heroin); Fentanyl and its derivatives; Hydromorphone; Methadone;
Morphine; Nicomorphine ; Oxycodone; Oxymorphone; Pentazocine;  Pethidine.
S8. CANNABINOIDS
All natural and synthetic cannabinoids are prohibited, e. g. :
* In cannabis (hashish, marijuana) and cannabis products
* Natural and synthetic tetrahydrocannabinols (THCs)
* Synthetic cannabinoids that mimic the effects of THC
Except
   * Cannabidiol
S9. GLUCOCORTICOIDS
All glucocorticoids are prohibited when administered by oral, intravenous, intramuscular or rectal routes.
including but not limited to :
Betamethasone; Budesonide ; Cortisone ; Deflazacort; Dexamethasone ; Fluticasone; Hydrocortisone;
Methylprednisolone; Prednisolone; Prednisone ; Triamcinolone
P1. BETA - BLOCKERS
Beta-blockers are prohibited In-Competition only, in the following sports, and also prohibited Out-of-Competition
where indicated
Archery (WA)*
Automobile (FIA)
Billiards (all disciplines) (WCBS)
Darts (WDF)
Golf (IGF)
Shooting (ISSF, IPC)*
Skiing/Snowboarding (FIS) in ski jumping, freestyle aerials/halfpipe and snowboard halfpipe/big air
Underwater sports (CMAS) in constant-weight apnoea with or without fins, dynamic apnoea with and without
fins, free immersion apnoea, Jump Blue apnoea, spearfishing, static apnoea, target shooting and variable weight
apnoea.
* Also prohibited Out-of-Competition

<!-- page 8 -->

I fldgi ( ^ I& fPoh - YS% ,xld m%cd;dka;s%l iudcjd§ ckrcfha w;s úfYI .eiÜ m;%h - 2020'01'24
PART I : SEC. (I) - GAZETTE EXTRAORDINARY OF THE  DEMOCRATIC SOCIALIST REPUBLIC OF SRI LANKA - 24.01.2020
8A
Including, but not limited to :
Acebutolol; Alprenolol; Atenolol; Betaxolol; Bisoprolol; Bunolol; Carteolol; Carvedilol; Celiprolol; Esmolol; Labetalol;
Metipranolol; Metoprolol; Nadolol; Oxprenolol; Pindolol; Propranolol; Sotalol  Timolol.
THE  2020  MONITORING   PROGRAMME *
The following substances are placed on the 2020 Monitoring Program :
1. Anabolic Agents : In and Out-of-Competition : ecdysterone
2. Beta-2-agonists : In and Out-of-Competition : any combination of beta -2 - agonists
3. 2-ethylsulfanyl-1H-benzimidazole (bemitil)  : In-and Out-of Competition
4. Stimulants : In-Competition only : bupropion, caffeine, nicotine, phenylephrine, phenylpropanolamine,
pipradrol and synephrine
5. Narcotics : In-Competition only : Codeine, hydrocodone and tramadol.
6. Glucocorticoids : In-competition (by routes of administration other than oral, intravenous, intramuscular
or rectal) and Out-of-competition (all routes of administration).
01 -313
PRINTED AT THE DEPARTMENT OF GOVERNMENT PRINTING, SRI LANKA.